| Filed On | Filing |
|---|---|
| 29 Oct 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Growth Portfolio Performance and Disciplined Execution Drive Strong Financial Results |
| 30 Jul 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Strong Performance Underscores Growth Portfolio Momentum and Pipeline Progress |
| 08 May 2026 | 8-K: Submission of Matters to a Vote of Security Holders |
| 30 Apr 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Financial Results Reflect Strong Execution and a Strengthened Foundation with Significant Pipeline Milestones Ahead |
| 05 Feb 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Financial results reflect disciplined execution and focus on delivering long-term growth |
| 12 Jan 2026 |
8-K: Regulation FD Disclosure
1 Bristol Myers Squibb: Built for Growth 44th Annual J.P. Morgan Healthcare Conference Christopher Boerner, Ph.D., Board Chair & CEO January 12th, 2026 |
| 18 Nov 2025 |
8-K: Other Events
PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) (“Bristol Myers Squibb”), today announced the accepted amounts and pricing terms of the previously announced tender offers to purchase for cash its outstanding n... |
| 10 Nov 2025 |
8-K: Other Events
FIRST SUPPLEMENTAL INDENTURE, dated as of November 10, 2025 (the “First Supplemental Indenture”), among BMS Ireland Capital Funding Designated Activity Company, a designated activity company incorporated under the laws of Ireland (the “I... |
| 03 Nov 2025 |
8-K: Other Events
(Princeton, N.J., November 3, 2025) – Bristol-Myers Squibb Company (NYSE:BMY) (“Bristol Myers Squibb” or the “Offeror”), announced the commencement of tender offers (“Offers”) to purchase for cash certain of its outstanding notes (collec... |
| 30 Oct 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Performance Marked by Continued Growth Portfolio Momentum, Pipeline Advancements and Strategic Business Development |
| 31 Jul 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Performance Underscores Continued Execution Against Long-Term Growth Strategy |
| 25 Jul 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development |
| 07 May 2025 | 8-K: Submission of Matters to a Vote of Security Holders |
| 24 Apr 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Results Reflect Continued Growth Portfolio Momentum and Disciplined Execution |
| 18 Feb 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers |
| 06 Feb 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Performance Reflects Progress Toward Delivering Sustained, Top-Tier Growth |
| 13 Jan 2025 |
8-K: Regulation FD Disclosure
43rd Annual J.P. Morgan Healthcare Conference January 13th, 2025 Christopher Boerner, Ph.D., Board Chair and Chief Executive Officer |
| 31 Oct 2024 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Performance Reflects Continued Focus on Near-Term Execution and Building a Foundation for Long-Term Sustainable Growth |
| 26 Jul 2024 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Results Underscore Continued Progress on Commercial Execution, Driving the Growth Portfolio and Pipeline Advancement |
| 18 Jun 2024 |
8-K: Departure/Election of Directors or Officers; Compensation
(Princeton, N.J., June 18, 2024) – Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has elected independent director Michael R. McMullen to the Board, effective July 1, 2024. Mr. McMullen will serve as a membe... |
Loading...